longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Agenus

AGEN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 3.54, above the reasonable range, cheaper than 11.2% of the time in the past 5 years, and the industry ranks 19/601, the industry Median -2.38.

3.54xP/E
$7.22Stock price
$2.04Earnings per share
3.54xP/E
Stock price$7.22Earnings per share$2.04

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-1.04x
Typical range
-3.45x–-0.27x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GRFSUSGRIFOLS SA
9.70x42.44%$5.09B
ACADUSAcadia Pharma
12.43x73.45%$4.73B
PURRUSHyperliquid Strategies
9.91x85.25%$2.54B
AUPHUSAurinia Pharma
7.18x54.40%$2.26B
ADMAUSAdma Biologics
11.86x35.42%$2.00B
LKFTUSLakefront Biotherapeutics
2.72x115.23%$1.88B
VORUSVor BioPharma
2.06x89.77%$1.30B
ABUSUSArbutus Pharma
6.52x533.09%$998.48M
RIGLUSRigel Pharma
2.66x83.91%$856.47M
BVNRYUSBavarian Nordic A/S
3.33x--$799.08M
IRWDUSIronwood Pharma
5.38x715.55%$698.96M
AGENUSAgenus
3.54x--$325.05M
QTTBUSQ32 Bio
9.57x162.23%$323.30M
CUVLUSClinuvel Pharmaceuticals
12.89x--$295.51M
CGENUSCompugen
6.62x173.68%$233.02M
PLXUSProtalix Biotherap
11.48x400.00%$217.54M
VXRTUSVaxart
3.15x328.57%$121.58M
RLYBUSRallybio
2.00x131.45%$91.13M
FBIOUSFortress Biotech
0.81x3,742.86%$83.71M
SPROUSSpero Therap
8.83x486.67%$65.22M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.